Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010250 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL19960742 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL15160679 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL30455536 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL21460614 | 0.99 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL16742394 | 0.99 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL30387296 | 0.99 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL30341663 | 0.99 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL2254751 | 0.99 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL5579268 | 0.97 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| US-11370778-B2 | Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases | Enterprise Therapeutics Limited (GB) | 2022-06-28 | — | — | US | disclosed |
| EP-3697788-B1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20200239442-A1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | Enterprise Therapeutics Limited (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| WO-2019077340-A1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | Enterprise Therapeutics Limited (GB) | 2019-04-25 | — | — | WO | disclosed |
| WO-2018096325-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | KMT2A 4337/4885EPHX2 4053/4885SMN1; SMN2 3415/4885 |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | CYP3A43, CYP2C9, CYP2C19 | KMT2A 4091/4885EPHX2 591/4885SMN1; SMN2 1397/4885 |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KMT2A 4508/4885EPHX2 3856/4885SMN1; SMN2 3788/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | KMT2A 4545/4885EPHX2 3496/4885SMN1; SMN2 2400/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KMT2A 4508/4885EPHX2 3856/4885SMN1; SMN2 3788/4885 |
| US-11370778-B2 | Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases | CFTR, SCNN1B, TRPV3 | KMT2A 2849/4885EPHX2 2126/4885SMN1; SMN2 4811/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KMT2A 4508/4885EPHX2 3856/4885SMN1; SMN2 3788/4885 |
| US-20210188855-A1 | COMPOUNDS | NHERF1, SCNN1B, SCNN1A | KMT2A 4270/4885EPHX2 3529/4885SMN1; SMN2 2572/4885 |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | KMT2A 4337/4885EPHX2 4053/4885SMN1; SMN2 3415/4885 |
| US-20200239442-A1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | CFTR, SCNN1B, TRPV3 | KMT2A 2849/4885EPHX2 2126/4885SMN1; SMN2 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.